The ESSENCE trial is one of the most significant studies in recent Type 2 diabetes research. Here’s what it found, what it means for semaglutide (Ozempic/Wegovy/Rybelsus), and what patients should know.
What Was the ESSENCE Trial?
The ESSENCE trial was a large-scale Phase 3 clinical trial evaluating semaglutide — the active ingredient in Ozempic (injectable) and Rybelsus (oral pill) — in adults with Type 2 diabetes who also had obesity or were overweight. The trial measured both blood sugar control (A1C reduction) and body weight outcomes over an extended period.
Key Findings
- Significant A1C reduction: Participants on semaglutide saw substantial drops in A1C — in many cases moving from diabetic to near-normal range
- Weight loss: Participants lost meaningful body weight, which itself improves insulin sensitivity and blood sugar control
- Cardiovascular benefit: Semaglutide reduced the risk of major cardiovascular events — heart attack, stroke, and cardiovascular death — in high-risk Type 2 diabetes patients
- Well tolerated: The most common side effects were gastrointestinal (nausea, vomiting), usually mild and resolving over time
What About Oral Semaglutide (Rybelsus)?
The FDA has approved oral semaglutide (brand name: Rybelsus) specifically to reduce the risk of major adverse cardiovascular events (MACE) — including heart attack, stroke, and cardiovascular death — in adults with Type 2 diabetes who already have cardiovascular disease.
This made semaglutide the first oral GLP-1 receptor agonist to carry a cardiovascular risk-reduction indication. Previously, only injectable GLP-1 drugs had this approval.
What Is Semaglutide and How Does It Work?
Semaglutide is a GLP-1 receptor agonist — a class of medications that mimics a hormone your gut naturally releases after eating. It works by:
- Stimulating insulin release when blood sugar is high
- Suppressing glucagon (a hormone that raises blood sugar)
- Slowing digestion, which reduces post-meal blood sugar spikes
- Reducing appetite, leading to weight loss
Forms of Semaglutide
| Brand Name | Form | Primary Use |
|---|---|---|
| Ozempic | Weekly injection | Type 2 diabetes management |
| Wegovy | Weekly injection | Weight management |
| Rybelsus | Daily oral pill | Type 2 diabetes management + MACE risk reduction |
What This Means for Type 2 Diabetes Patients
The ESSENCE trial findings and subsequent FDA approvals confirm that semaglutide is among the most effective Type 2 diabetes medications available. For patients who also have cardiovascular disease, it now addresses both blood sugar control and heart risk simultaneously.
If you have Type 2 diabetes and are interested in semaglutide, speak with your doctor about whether Ozempic or Rybelsus is appropriate for your situation — including insurance coverage, which can be a significant practical factor.

